Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Blast Crisis 1

Interventions

Cytarabine 11Cyclophosphamide 10Filgrastim 9Etoposide 8fludarabine phosphate 6Vorinostat 6Tacrolimus 6Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Dasatinib 6Carboplatin 5tipifarnib 4sargramostim 4Topotecan 4Sirolimus 4Bortezomib 4tanespimycin 3fludarabine 3alvocidib 3Whole-Body Irradiation 3Sorafenib 3Flow Cytometry 3Doxorubicin 3Decitabine 3Busulfan 3Antilymphocyte Serum 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3laromustine 2entinostat 2bryostatin 1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blast Crisis × irofulven × Clear all
NCT00003997 2013-02-08

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡